The cornerstone of this investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the company’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new centre will produce small molecules, peptides and oligonucleotides.

AstraZeneca’s largest single manufacturing investment in the world

The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca’s largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production, describes the company.

“I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation’s domestic supply chain. Advanced manufacturing is at the heart of Virginia’s dynamic economy, so I am thrilled that AstraZeneca, one of the world’s leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth,” says Governor Glenn Youngkin, Commonwealth of Virginia.

The USD 50 billion investment

The USD 50 billion investment across the company’s R&D and manufacturing footprint in the US over the next five years also includes the expansion of our R&D facility in Gaithersburg, Maryland, an R&D centre in Kendall Square, Cambridge, Massachusetts, next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California, continuous manufacturing expansion in Mount Vernon, Indiana, specialty manufacturing expansion in Coppell, Texas, new sites to supply clinical trials and the company’s research and development investment in novel medicines.

This multi-billion dollar capital investment is in addition to the USD 3.5 billion announced in November 2024.